MedTrace Logo

Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes

NCT03558386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2020-12-02

No results posted yet for this study

Summary

This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).

Conditions

Interventions

BEHAVIORAL

ePRO survey

An electronic patient reported outcomes survey will be completed by the patient.

Sponsors & Collaborators

Principal Investigators

  • Bronwen E Shaw, MD, PhD · Center for International Blood and Marrow Transplant Research (CIBMTR)/Medical College of Wisconsin

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2019-11-15
Completion
2019-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03558386 on ClinicalTrials.gov